To ensure all regulatory and governance requirements are met, it is essential that investigators obtain advice and support from those with specialist knowledge relating to Investigational Medicinal product (IMP) supplies (for example from a Clinical Trial Pharmacist, Clinical Trials Unit (CTU) or Contract Research Organisation (CRO)).
Advice should be sought early in the trial planning process as requirements may impact on trial design and any funding application.
A Trial Supplies Guide (pdf, 511.55 KB) has been developed to:
- Introduce Chief Investigators (and others involved in organising IMP supplies) to the language and complexities surrounding these activities (including a Trial Supplies Checklist).
- To provide Pharmacy staff with a comprehensive guide covering all aspects relating to the manufacture, supply, assembly, labelling, blinding and costing of trial supplies, as well as consideration for the pharmacy documentation required for clinical trials.
The status of the IMP used in a clinical trial influences the reference document that may be required. The MHRA Risk-adapted Approaches to the Management of Clinical Trials of Investigational Medicinal Products (PDF) gives the following guidance:
"If the IMP is authorised in any EU Member State and is used according to the terms of the marketing authorisation, the Summary of Product Characteristics (SmPC) will replace the Investigator’s Brochure. If the IMP is authorised in an ICH country (USA or Japan) a copy of the prescriber’s information (equivalent to the SmPC) will replace the Investigator’s Brochure.
If this document is originally in a language other than English, an English translation should be provided.
When the conditions of use in the clinical trial differ from those authorised, the SmPC or equivalent should be complemented with a summary of relevant data that support the use of the IMP in the clinical trial. This can be provided as an Investigator’s Brochure or, in some cases, may be incorporated into the protocol.’"
Where an Investigator's Brochure (IB) is required for a non-commercial trial, it may be supplied by the Marketing Authorisation Holder of the IMP under trial. If it cannot be obtained from the Marketing Authorisation Holder or the IMP is being developed ‘in house’, the sponsor must ensure that an IB is produced.
On 15 October 2018, the HRA launched a Pharmacy Assurance process for studies involving Investigational Medicinal Products (IMPs) which has been tested and is going through a phased roll-out across the UK. The process involves the completion of one single pharmacy technical review per study, which can be used by all participating sites. This streamlined approach to pharmacy assessment will allow local NHS/HSC organisations to assess and confirm local capacity and capability more effectively, providing substantial benefits to efficient study set-up. The HRA website provides further information.